Evidence map›Paper›PMID 40266222›Full record

ArticleVaccines2025

Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults.

Natalia Castillo Almeida, Lalitha Parameswaran, Elliot N DeHaan, Hayley Wyper, Farah Rahman, Qin Jiang, Wen Li, Michael Patton, Maria Maddalena Lino, Zaynah Majid-Mahomed and 11 more

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Trial
  2. Vaccination in systemic lupus erythematosus.Human vaccines & immunotherapeutics · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Natalia Castillo AlmeidaDepartment of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-9904-7137
Lalitha ParameswaranDepartment of Internal Medicine, Division of Infectious Diseases, NYU Grossman School of Medicine, New York, NY 10016, USA.ORCID 0009-0000-2750-5357
Elliot N DeHaanVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Hayley WyperVaccine Research & Development, Pfizer Ltd., Marlow SL7 1YL, UK.
Farah RahmanVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.ORCID 0000-0001-8696-8730
Qin JiangVaccine Research & Development, Pfizer Inc., Collegeville, PA 19426, USA.ORCID 0000-0001-8233-8993
Wen LiVaccine Research & Development, Pfizer Inc., Collegeville, PA 19426, USA.
Michael PattonVaccine Research & Development, Pfizer Ltd., Marlow SL7 1YL, UK.
Maria Maddalena LinoVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Zaynah Majid-MahomedVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Elissa MalkinGeorge Washington University Vaccine Research Unit, George Washington University, Washington, DC 20052, USA.
Matthew DavisRochester Clinical Research, Inc., Rochester, NY 14609, USA.
William J TownerSouthern California Permanente Medical Group, Kaiser Permanente Southern California, Los Angeles, CA 90027, USA.ORCID 0000-0001-5645-2979
Kapil SahariaUniversity of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201, USA.ORCID 0000-0002-5116-0042
Kumar IlangovanVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.ORCID 0009-0002-0327-9265
Elena KalininaVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
David CooperVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Kena A SwansonVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.ORCID 0000-0002-3389-8414
Annaliesa S AndersonVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Alejandra GurtmanVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Iona MunjalVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.

Funding

Pfizer Inc N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adultsimmunocompromisedimmunogenicityrenally impairedRSVRSVpreFsafety

Identifiers

PMID40266222
PMCPMC11946143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.